- Lonza and Genetix Biotherapeutics have extended their long-term manufacturing agreement to support growing demand for the gene therapy ZYNTEGLO™.
- Commercial production will continue at Lonza’s Houston facility, with plans to expand manufacturing capacity and support future Genetix therapies.
Lonza and Genetix Biotherapeutics Inc. have extended their long-term commercial manufacturing agreement to support demand for ZYNTEGLO™, a gene therapy approved in the United States for pediatric and adult patients with transfusion-dependent beta-thalassemia.
Under the renewed agreement, Lonza will expand manufacturing capacity for the therapy as part of its contract development and manufacturing organization (CDMO) services. Commercial production will continue at Lonza’s Houston, Texas, facility, a cell and gene therapy site with nearly 10 years of combined clinical and commercial manufacturing experience supporting the treatment.
The collaboration between the companies began in 2013 and contributed to the commercial approval of ZYNTEGLO™ in 2022. The updated agreement also includes provisions to scale manufacturing in the future to support additional therapies being developed by Genetix.
“Our extended agreement with Genetix underscores the value of our services and expertise in commercial cell and gene therapy manufacturing. We are proud to continue our collaboration by expanding the commercial production of ZYNTEGLO™ at our state-of-the-art manufacturing facility in Houston.”
Daniel Palmacci, Head of Specialized Modalities at Lonza
Genetix said the extended agreement supports its strategy to meet increasing patient demand for its therapies while maintaining a reliable supply through its contract manufacturing partnership with Lonza.
